09-2019-InflaRx Reports Second Quarter 2019 Financial & Operating Results
(WorldNews Netherlands)

InflaRx Reports Second Quarter 2019 Financial & Operating Results IFX-1in Hidradenitis Suppurativa did not meet the primary endpoint; trial ongoing - multiple efficacy signals for high-dose group identified First patient treated in Pyoderma Gangraenosum phase IIa trial Second phase II clinical trial commenced inANCA-associated vasculitis Cash and cash equivalents plus securities and other investments of EUR138.3 million as of June 30, 2019 Jena, Germany, 14 August 2019- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported financial and operating results for the second quarter ended...